SpyGlass Pharma has filed a notice of an exempt offering of securities to raise $90,019,986.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, SpyGlass Pharma is raising $90,019,986.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Patrick Mooney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About SpyGlass Pharma
SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.
To learn more about SpyGlass Pharma, visit http://www.spyglasspharma.com/
Contact:
Patrick Mooney, Chief Executive Officer
949-284-6904
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.